- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Nanox Adds AI Applications to Teleradiology Platform for CT Second Opinions
Facilitating additional consultation on chest and abdominal CT scans, the Second Opinions teleradiology platform now features FDA-cleared AI tools for cardiac, bone and liver assessments.
In an attempt to enhance connections between patients, radiologists, and other subspecialty providers, Nanox has added three artificial intelligence (AI) tools to its Second Opinions teleradiology platform for chest and abdominal computed tomography (CT) scans.
The three AI tools, HealthCCSng, HealthOST and HealthFLD, have previously garnered 510(k) clearance from the Food and Drug Administration (FDA).
HealthOST, which can identify low bone mineral density (BMD) and aid in the detection of compression fractures, is one of three FDA-cleared AI tools that have been added to Nanox's Second Opinions teleradiology platform for chest and abdominal CT scans. (Image courtesy of Nanox.)
Nanox said HealthCCSng enables detection of coronary artery calcium, which can be an early indicator of coronary artery disease (CAD). Other integrated AI-powered tools include HealthFLD, which may facilitate detection of fatty liver disease through liver density measurements, and HealthOST, which can identify low bone mineral density (BMD) and aid in the detection of compression fractures, according to Nanox.
“The integration of Nanox.AI’s solutions into the Second Opinions service will help empower radiologists and other healthcare providers by providing them with advanced AI tools that aim to improve patient outcomes,” noted Erez Meltzer, the chief executive officer of Nanox. “We will continue exploring opportunities to leverage our AI technology to promote accessible early diagnosis and preventative management.”
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
